Covidien Plc plans to buy Somanetics Corp. for US$25 a share in cash, according to reports. The deal valued at US$250mn. Covidien said the acquisition would broaden its medical equipment product offerings and create earnings growth over time. The deal values Somanetics at a premium of US$6.10, or 32%, over its closing price of US$18.9 a share on 15th June.
- Expectation, Highlights and Live Updates on Budget 2016.
- Get the most detailed result analysis on the web - Real Fast!
- Actionable & Award-Winning Research on 500 Listed Indian Companies.